↓ Skip to main content

Dove Medical Press

Article Metrics

Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism

Overview of attention for article published in Vascular Health and Risk Management, January 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#31 of 447)
  • High Attention Score compared to outputs of the same age (86th percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news
1 news outlet
twitter
3 tweeters

Citations

dimensions_citation
62 Dimensions

Readers on

mendeley
94 Mendeley
Title
Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism
Published in
Vascular Health and Risk Management, January 2015
DOI 10.2147/vhrm.s63060
Pubmed ID
Authors

John Eikelboom, Vinai Bhagirath, Noel C Chan, John W Eikelboom

Abstract

Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is a common and potentially preventable cause of morbidity and mortality. Unfractionated heparin, low-molecular-weight heparin, and warfarin have been the cornerstone of VTE prevention and treatment but are being replaced by recently approved non-vitamin K antagonist oral anticoagulants (NOACs): dabigatran, rivaroxaban, apixaban, and edoxaban. The NOACs are at least as effective and as safe as heparins and warfarin for VTE prevention and treatment and are more convenient because they have a low propensity for food and drug interactions and are given in fixed doses without routine coagulation monitoring. The remaining limitations of currently available NOACs include their dependence on renal and hepatic function for clearance, and the lack of an approved antidote. Betrixaban is a new NOAC with distinct pharmacological characteristics: minimal renal clearance, minimal hepatic metabolism, and long half-life. It has undergone successful Phase II studies in orthopedic thromboprophylaxis, and in stroke prevention in atrial fibrillation. Currently, it is being evaluated in a Phase III trial of extended thromboprophylaxis in medical patients (APEX study). In this article, we describe the development of betrixaban, review its pharmacological profile, discuss the results of clinical trials, and examine its potential for VTE prevention and treatment.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 94 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Chile 1 1%
Slovenia 1 1%
Unknown 92 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 15 16%
Student > Master 14 15%
Student > Postgraduate 13 14%
Researcher 10 11%
Other 8 9%
Other 24 26%
Unknown 10 11%
Readers by discipline Count As %
Medicine and Dentistry 55 59%
Pharmacology, Toxicology and Pharmaceutical Science 11 12%
Agricultural and Biological Sciences 8 9%
Unspecified 1 1%
Nursing and Health Professions 1 1%
Other 4 4%
Unknown 14 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 February 2017.
All research outputs
#944,718
of 9,018,604 outputs
Outputs from Vascular Health and Risk Management
#31
of 447 outputs
Outputs of similar age
#31,708
of 232,588 outputs
Outputs of similar age from Vascular Health and Risk Management
#2
of 22 outputs
Altmetric has tracked 9,018,604 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 447 research outputs from this source. They receive a mean Attention Score of 3.3. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 232,588 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.